Genmab maintains 2026 revenue guidance at $4.33 billion to $4.53 billion
GMAB•Genmab maintained its 2026 revenue guidance at $4.33 billion to $4.53 billion, implying 19% growth at the midpoint. It forecasts adjusted operating profit of $1.07 billion to $1.39 billion.
1. 2026 outlook
Genmab maintained its 2026 revenue guidance at $4.33 billion to $4.53 billion, implying 19% growth at the midpoint. Adjusted operating profit is forecast at $1.07 billion to $1.39 billion, with adjusted operating expenses of $2.81 billion to $2.95 billion.
2. Development spending
Spending targets accelerated late-stage development of petosemtamab and Rina-S, alongside launch preparations. EPKINLY sales and continued royalty portfolio momentum support the revenue outlook.
3. Nine-month results
Nine-month revenue rose 22% to $3.24 billion, while adjusted operating profit increased 9% to $1.11 billion.
